Affiliation:
1. Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology,
Mesra, Ranchi- 835215, Jharkhand, India
2. School of Pharmaceutical Sciences, Siksha 'O' Anusandhan University,
Bhubaneswar-751003, Odisha, India
3. Department of Pharmacy, Guru Ghasidas Central University, Bilaspur-495009,
Chhattisgarh, India
Abstract
Background:
As the COVID era unfolds, researchers reveal that rapid changes in viral genetic
material allow viruses to circumvent challenges triggered by the host immune system and resist
anti-viral drugs, potentially leading to persistent viral manifestations in host cells. Molnupiravir
(RNA-dependent RNA polymerase inhibitor) is a novel anti-viral medicine promising a vital role in
coming setbacks.
Objectives::
This review aims to clarify the safety and efficacy of the molnupiravir molecule in light of
existing case studies. As a result, it is intended to explore and discuss the molecular structure, mechanism
of action, discovery and development process, preclinical research, clinical investigations, and
other subtopics.
Methods:
A total of 75 publications were searched using multiple engines, such as Google Scholar,
PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrials.gov, and others, with a constraint
applied to exclude publications published over 11 years ago. Molnupiravir, safety, efficacy, COVID-
19, RdRp, PK-PD, and clinical study were utilized as keywords.
Result:
Clinical results on molnupiravir are supported by investigations that were recently disclosed
in a study on both sex volunteers (male and female) with an age restriction of 19 to 60 years, followed
by a Phase-3 Clinical Trial (NCT04575584) with 775 randomly assigned participants and no fatalities
reported due to treatment.
Conclusion:
Molnupiravir proved a high level of safety, allowing it to be tested further. This review
supports the safety and efficacy of this molecule based on the established evidence, which claims the
most anticipated employment of molnupiravir in COVID protocol.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference75 articles.
1. Cascella M.; Rajnik M.; Aleem A.; Features, evaluation, and treatment of coronavirus (COVID-19) 2022
2. Aleem A.; Akbar Samad A.B.; Slenker A.K.; Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19) 2022
3. Singh A.; Singh R.S.; Sarma P.; A comprehensive review of animal models for coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV. Virol Sin 2020,35(3),290-304
4. Liang Y.; Wang M.L.; Chien C.S.; Highlight of immune pathogenic response and hematopathologic effect in SARS-COV, mers-cov, and SARS-COV-2 infection. Front Immunol 2020,11,1022
5. Khoo S.H.; Fitzgerald R.; Fletcher T.; Optimal dose and safety of molnupiravir in patients with early SARS-COV-2: A phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother 2021,76(12),3286-3295